Author: Andrew Celentano - Page 11 - Start Medical Product Development

Sumbu Unveils World’s First Dual-Vector Consumer Exoskeleton at CES 2026

January 3, 2026

LAS VEGAS, Jan. 3, 2026 /PRNewswire/ — Today at CES 2026, Sumbu announced its Exo-S3 line of dual-vector exoskeletons designed for the general public: the Exo-S3, Exo-S3 Pro and Exo-S3 Ultra. The series is the world’s first commercially available dual-vector exoskeleton designed to support human movement across real-world terrain. This release establishes a new market for lightweight, AI-powered wearable mobility products.

AI model predicts B cell reactivity to neoantigens for improved cancer vaccines

January 2, 2026

Professor Jung Kyoon Choi’s research team from the Department of Bio and Brain Engineering, in collaboration with Neogen Logic Co., Ltd., developed the new AI model to predict neoantigens.

FDA Clears BrainSpace Intellidrop, an automated neuro device that addresses ICU nursing shortages and builds training data for Physical AI

January 2, 2026

SEATTLE, Jan. 2, 2026 /PRNewswire/ — BrainSpace, a medical technology company building automated solutions for neuro injury, illness and degeneration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Intellidrop.

HAI Solutions Receives FDA De Novo Grant for QIKCAP System

January 2, 2026

HAI Solutions, a leading innovator in ultraviolet (UVC) microbial reduction medical devices, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo classification for its QIKCAP System. This marks the first and only FDA-Granted Ultraviolet light-based microbial reduction device for luer-activated valves, establishing a new Class II medical device category.